Peptide Schedule
Cardiogen4 residuesAEDREach bubble = one amino acid. Size = residue mass. Color = chemical class.Cardiogen
Benefits
About Cardiogen
Cardiogen is a synthetic tetrapeptide bioregulator with the amino acid sequence Ala-Glu-Asp-Arg (AEDR), developed at the St. Petersburg Institute of Bioregulation and Gerontology as part of Professor Vladimir Khavinson's program of tissue-specific short peptide regulators. It belongs to the "cytogen" class of bioregulators — synthesized short-chain peptides designed to target specific organ systems, in this case cardiac and cardiovascular tissue. Unlike larger peptide therapeutics that bind cell-surface receptors, Khavinson bioregulators are proposed to penetrate cell membranes and interact directly with DNA at specific promoter regions, modulating gene expression in a tissue-specific manner. In preclinical studies using organotypic tissue cultures from both young and old rats, cardiogen at picomolar concentrations stimulated cardiomyocyte proliferation — an effect that wasn't reproduced by any of the 20 individual L-amino acids tested at the same concentration. This suggests the intact tetrapeptide sequence is required for bioactivity. Immunohistochemical analysis showed cardiogen reduced p53 protein expression in myocardial tissue, indicating suppression of apoptotic pathways. Published evidence is limited to in vitro experiments and animal models, primarily from a single research group. No randomized controlled trials in humans have been published in Western peer-reviewed journals.
Who Should Consider Cardiogen
- Researchers studying cardiac tissue bioregulation and gene expression
- Individuals interested in cardiovascular aging and cardioprotection
- Those following Khavinson bioregulator protocols for heart health
- Preclinical investigators studying peptide-DNA interactions in cardiac cells
How Cardiogen Works
Cardiogen is proposed to operate through the peptide-DNA interaction mechanism described by Khavinson's bioregulation theory. As a short tetrapeptide, it's small enough to cross cell membranes without receptor-mediated transport and enter the nucleus, where it reportedly binds to histone proteins H1, H2b, H3, and H4. This interaction alters chromatin conformation, increasing the transcriptional availability of cardiac-specific gene promoter regions. The downstream effects include upregulation of genes encoding myocardial structural proteins (myosin heavy chain, troponin I, titin), mitochondrial biogenesis regulators (PGC-1alpha, TFAM), and anti-apoptotic factors (Bcl-2, Akt). In cardiac tissue culture experiments, cardiogen at picomolar concentrations activated cytoskeletal and nuclear matrix protein synthesis, stimulating cell proliferation while reducing apoptosis through p53 downregulation.
What to Expect
No noticeable effects expected. The bioregulator is proposed to begin interacting with cardiac gene expression pathways at the cellular level.
Continued gene expression modulation according to the bioregulation model. Some users anecdotally report improved exercise tolerance, though this hasn't been validated in clinical studies.
Completion of the standard treatment course. Any effects on cardiac gene expression are proposed to persist beyond the dosing period due to epigenetic mechanisms.
The bioregulatory effects are theorized to continue for several months after the course ends, with cumulative benefits from repeated courses over time.
Dosing Protocol
| Level | Dose / Injection | Frequency |
|---|---|---|
| Beginner | 10mg | Daily |
| Moderate | 20mg | Daily |
| Aggressive | 20mg | 2x Daily |
Note: Cardiogen (Ala-Glu-Asp-Arg) is a synthetic tetrapeptide bioregulator developed by Professor Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology. It's typically sold as oral capsules containing 20 mg of the active peptide complex. Standard protocols involve 10-20 day oral courses repeated every 3-6 months.
How to Inject Cardiogen
Take 1 capsule once or twice daily, 15-20 minutes before a meal, with a small amount of water. Do not chew or open the capsule. A standard treatment course lasts 10-20 days and can be repeated every 3-6 months. Morning administration is generally preferred for optimal absorption.
Cycling Protocol
Standard Khavinson bioregulator protocol: 1-2 capsules daily for 10-20 consecutive days, repeated every 3-6 months. Courses are often combined with other organ-specific bioregulators.
Pharmacokinetics
Source: Estimated from general tetrapeptide degradation kinetics; no published PK data specific to cardiogen.
Loading the interactive decay curve.
Side Effects
Cardiogen has no established adverse effect profile in humans due to the absence of controlled clinical trials. In preclinical animal studies, no significant toxicity or adverse effects have been reported at standard experimental doses. As a tetrapeptide composed of common L-amino acids (alanine, glutamic acid, aspartic acid, arginine), it's expected to have low inherent toxicity. Theoretical concerns include potential allergic reactions to capsule excipients and unknown effects of chronic oral administration.
Contraindications
- Pregnancy and breastfeeding (no safety data available)
- Known hypersensitivity to any component of the capsule formulation
- Acute myocardial infarction or unstable angina (seek emergency medical care instead)
- Children under 18 (no pediatric safety data)
- Should not be used as a substitute for evidence-based cardiovascular medications
Drug Interactions
- No formal drug interaction studies have been conducted
- May be combined with other Khavinson bioregulators per standard Russian protocols
- Use caution when combining with any cardiac medications — consult a physician
Storage & Stability
Molecular Profile
Related Peptides
References
- The effect of the amino acids and cardiogen on the development of myocard tissue culture from young and old ratsPubMed 20210190
- Tumor-modifying effect of cardiogen peptide on M-1 sarcoma in senescent ratsPubMed 20396706
- The tissue-specific effect of synthetic peptides-biologic regulators in organotypic tissues culturePubMed 17152728
- Peptide regulation of aging: 35-year research experiencePubMed 19902107